Our results suggest that although no chemical inhibitors have been designed with the specific goal of targeting APLP2, existing beta-secretase inhibitors that have been made to target APP for the treatment of Alzheimer's disease may potentially be repurposed to target APLP2. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.